1. Volume 123, Issue 6, Pages 1831-1838 (December 2002)
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection 
Ching–Lung Lai, Mohamed Rosmawati, Judy Lao, Hans Van Vlierberghe, Frank H. Anderson, Neal Thomas, Deborah Dehertogh 
Gastroenterology 
Volume 123, Issue 6, Pages (December 2002)
DOI: /gast
Copyright © 2002 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Mean log10 change in HBV-DNA levels by Amplicor PCR. HBV-DNA serum levels were evaluated by PCR at baseline and weeks 4, 12, and 22. Patients received once-daily doses of (♦) 0.01 mg entecavir, (□) 100 mg lamivudine, (■) 0.1 mg entecavir, or (●) 0.5 mg entecavir. P = for 0.1 mg/day and 0.5 mg/day entecavir vs. 100 mg/day of lamivudine.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions